
Yoshiaki Nakamura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4905078/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nature Medicine, 2020, 26, 1859-1864.	30.7	209
2	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clinical Cancer Research, 2019, 25, 7035-7045.	7.0	152
3	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nature Reviews Clinical Oncology, 2021, 18, 473-487.	27.6	139
4	CIRCULATEâ€Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science, 2021, 112, 2915-2920.	3.9	74
5	A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. Clinical Cancer Research, 2021, 27, 3714-3724.	7.0	61
6	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 198-205.	2.3	57
7	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. Oncologist, 2018, 23, 1310-1318.	3.7	40
8	Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. JCO Precision Oncology, 2022, 6, e2100181.	3.0	33
9	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy. Clinical Cancer Research, 2022, 28, 2110-2117.	7.0	30
10	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2021, 20, 113-120.e1.	2.3	22
11	Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open, 2020, 5, e000600.	4.5	20
12	A Krukenberg Tumor from an Occult Intramucosal Gastric Carcinoma Identified during an Autopsy. Case Reports in Oncological Medicine, 2014, 2014, 1-5.	0.3	11
13	Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. JCO Precision Oncology, 2020, 4, 1407-1413.	3.0	9
14	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	1.6	9
15	FMSâ€ŀike tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer. Cancer Science, 2021, 112, 314-322.	3.9	8
16	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO Precision Oncology, 2022, 6, e2100383.	3.0	8
17	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. Clinical Cancer Research, 2022, 28, 3480-3488.	7.0	8
18	HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naìve, HER2-amplified metastatic colorectal cancer. ESMO Open, 2019, 4, e000530.	4.5	7

#	Article	IF	CITATIONS
19	Rapid Screening Using Pathomorphologic Interpretation to Detect <i>BRAF</i> V600E Mutation and Microsatellite Instability in Colorectal Cancer. Clinical Cancer Research, 2022, 28, 2623-2632.	7.0	4
20	Pertuzumab Plus Trastuzumab for Treatment-Refractory <i>HER2</i> -Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm. JCO Clinical Cancer Informatics, 2022, , .	2.1	3
21	Development ofHER2-targeted Therapies for Gastrointestinal Cancer. European Oncology and Haematology, 2020, 16, 29.	0.0	0